Cochlear Limited

BRSE:OC5 Stock Report

Market Cap: CHF 3.8b

Cochlear Valuation

Is OC5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of OC5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: OC5 (CHF55.05) is trading below our estimate of future cash flow value (CHF129.86)

Significantly Below Future Cash Flow Value: OC5 is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OC5?

Key metric: As OC5 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for OC5. This is calculated by dividing OC5's market cap by their current earnings.
What is OC5's PE Ratio?
PE Ratio19.6x
EarningsAU$345.30m
Market CapAU$6.79b

Price to Earnings Ratio vs Peers

How does OC5's PE Ratio compare to its peers?

The above table shows the PE ratio for OC5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average51.6x
MOVE Medacta Group
30.4x12.41%CHF 2.7b
SOON Sonova Holding
22.2x10.23%CHF 11.9b
MED Medartis Holding
112.1x42.50%CHF 936.0m
STMN Straumann Holding
41.8x16.05%CHF 14.9b
OC5 Cochlear
19.6x7.84%CHF 6.8b

Price-To-Earnings vs Peers: OC5 is good value based on its Price-To-Earnings Ratio (19.6x) compared to the peer average (51.6x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does OC5's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OC5 19.6xIndustry Avg. 24.8xNo. of Companies12PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: OC5 is good value based on its Price-To-Earnings Ratio (19.6x) compared to the European Medical Equipment industry average (24.8x).

Price to Earnings Ratio vs Fair Ratio

What is OC5's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OC5 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio19.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate OC5's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OC5 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 55.05
CHF 69.84
+26.86%
15.15%CHF 95.44CHF 53.33n/a15
Jun ’27n/a
CHF 70.17
0%
14.98%CHF 95.74CHF 53.50n/a15
May ’27n/a
CHF 70.98
0%
15.97%CHF 95.71CHF 53.49n/a15
Apr ’27n/a
CHF 134.70
0%
12.77%CHF 166.33CHF 106.84n/a15
Mar ’27n/a
CHF 137.37
0%
12.53%CHF 166.11CHF 114.74n/a14
Feb ’27n/a
CHF 163.50
0%
9.40%CHF 188.83CHF 129.48n/a15
Jan ’27n/a
CHF 159.50
0%
9.25%CHF 187.16CHF 126.18n/a15
Dec ’26n/a
CHF 158.22
0%
9.25%CHF 185.67CHF 125.17n/a15
Nov ’26n/a
CHF 156.97
0%
9.30%CHF 183.39CHF 123.64n/a15
Oct ’26n/a
CHF 161.00
0%
9.32%CHF 187.69CHF 126.53n/a15
Sep ’26n/a
CHF 161.85
0%
10.02%CHF 185.92CHF 125.34n/a16
Aug ’26n/a
CHF 151.73
0%
9.72%CHF 184.78CHF 122.14n/a16
Jul ’26n/a
CHF 150.20
0%
8.43%CHF 174.70CHF 121.94n/a16
Jun ’26n/a
CHF 152.82
0%
7.69%CHF 176.54CHF 125.21n/a16
May ’26n/a
CHF 149.39
0%
7.69%CHF 172.58CHF 122.40n/a16
Apr ’26n/a
CHF 159.59
0%
7.68%CHF 183.86CHF 130.40n/a16
Mar ’26n/a
CHF 165.20
0%
7.65%CHF 190.19CHF 134.89n/a15
Feb ’26n/a
CHF 169.22
0%
10.39%CHF 195.25CHF 127.34n/a15
Jan ’26n/a
CHF 165.39
0%
10.43%CHF 193.46CHF 126.17n/a14
Dec ’25n/a
CHF 169.45
0%
10.57%CHF 198.45CHF 129.42n/a14
Nov ’25n/a
CHF 165.27
0%
10.14%CHF 196.02CHF 127.84n/a14
Oct ’25n/a
CHF 167.00
0%
10.74%CHF 200.49CHF 130.75n/a14
Sep ’25n/a
CHF 163.14
0%
11.70%CHF 198.54CHF 129.48n/a15
Aug ’25n/a
CHF 163.20
0%
13.81%CHF 207.44CHF 125.03n/a15
Jul ’25n/a
CHF 168.85
0%
13.20%CHF 219.38CHF 132.23n/a16
Jun ’25n/a
CHF 170.85
0%
13.20%CHF 221.98CHF 133.79n/a16
CHF 66.01
Fair Value
16.6% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/14 08:39
End of Day Share Price 2026/06/08 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cochlear Limited is covered by 26 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Saul HadassinBarrenjoey Markets Pty Limited
Stuart RobertsBell Potter
Elisabeth Decou CliveBernstein